Market Overview

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Related MYL
UPDATE: Mylan Launches First Generic ORTHO EVRA Patch
Mylan Inks Two Separate Agreements - Analyst Blog
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)
Related PFE
Portola's Betrixaban Study Design Published - Analyst Blog
Tax Dodging Companies Cost You More Than $1,200 Each Year
Investors: Brace for a Turbulent Second Quarter (Fox Business)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Posted-In: News FDA

 

Most Popular

Related Articles (MYL + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free